Development and Validation of a Nonremission Risk Prediction Model in First-Episode Psychosis: An Analysis of 2 Longitudinal Studies.
early intervention
logistic regression
precision medicine
prognosis
psychotic disorders
schizophrenia
Journal
Schizophrenia bulletin open
ISSN: 2632-7899
Titre abrégé: Schizophr Bull Open
Pays: United States
ID NLM: 101770329
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
28
9
2021
Statut:
epublish
Résumé
Psychosis is a major mental illness with first onset in young adults. The prognosis is poor in around half of the people affected, and difficult to predict. The few tools available to predict prognosis have major weaknesses which limit their use in clinical practice. We aimed to develop and validate a risk prediction model of symptom nonremission in first-episode psychosis. Our development cohort consisted of 1027 patients with first-episode psychosis recruited between 2005 and 2010 from 14 early intervention services across the National Health Service in England. Our validation cohort consisted of 399 patients with first-episode psychosis recruited between 2006 and 2009 from a further 11 English early intervention services. The one-year nonremission rate was 52% and 54% in the development and validation cohorts, respectively. Multivariable logistic regression was used to develop a risk prediction model for nonremission, which was externally validated. The prediction model showed good discrimination C-statistic of 0.73 (0.71, 0.75) and adequate calibration with intercept alpha of 0.12 (0.02, 0.22) and slope beta of 0.98 (0.85, 1.11). Our model improved the net-benefit by 15% at a risk threshold of 50% compared to the strategy of treating all, equivalent to 15 more detected nonremitted first-episode psychosis individuals per 100 without incorrectly classifying remitted cases. Once prospectively validated, our first episode psychosis prediction model could help identify patients at increased risk of nonremission at initial clinical contact.
Identifiants
pubmed: 34568827
doi: 10.1093/schizbullopen/sgab041
pii: sgab041
pmc: PMC8458108
doi:
Types de publication
Journal Article
Langues
eng
Pagination
sgab041Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Type : ErratumIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the University of Maryland's school of medicine, Maryland Psychiatric Research Center.
Références
PLoS One. 2019 Mar 7;14(3):e0212846
pubmed: 30845268
Lancet Psychiatry. 2016 Oct;3(10):935-946
pubmed: 27569526
Br J Psychiatry. 2017 Dec;211(6):350-358
pubmed: 28982659
Med Decis Making. 2006 Nov-Dec;26(6):565-74
pubmed: 17099194
Eur Heart J. 2014 Aug 1;35(29):1925-31
pubmed: 24898551
Stat Med. 2019 Mar 30;38(7):1276-1296
pubmed: 30357870
Ann Intern Med. 2015 Jan 6;162(1):W1-73
pubmed: 25560730
J Clin Psychiatry. 2014 Jun;75(6):e566-72
pubmed: 25004197
Lancet Digit Health. 2019 Oct;1(6):e261-e270
pubmed: 33323250
JAMA Psychiatry. 2018 Nov 1;75(11):1156-1172
pubmed: 30267047
Am J Epidemiol. 2015 Sep 15;182(6):528-34
pubmed: 26337075
Lancet Psychiatry. 2020 Jul;7(7):602-610
pubmed: 32563307
Schizophr Bull. 2017 Jul 1;43(4):843-851
pubmed: 28199703
Br J Psychiatry. 2012 Dec;201(6):481-5
pubmed: 22955007
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
BJPsych Bull. 2019 Feb;43(1):8-16
pubmed: 30261942
Psychol Med. 2021 Jan;51(1):44-53
pubmed: 31462334
Am J Psychiatry. 2005 Mar;162(3):441-9
pubmed: 15741458
Early Interv Psychiatry. 2014 Feb;8(1):59-67
pubmed: 23347742
World Psychiatry. 2013 Oct;12(3):216-26
pubmed: 24096780